X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-10-08 | ACET | Adicet Bio, Inc. | Orbimed Advisors LLC | 10% | P - Purchase | $1.00 | +5,000,000 | 7,420,781 | +207% | +$5,000,000 | ||||||
| D | 2025-10-10 | ZVRA | Zevra Therapeutics, Inc. | McFarlane Neil F. | Pres, CEO | S - Sale+OE | $10.82 | -19,500 | 222,016 | -8% | -$210,908 | |||||
| M | 2025-10-08 | LVTX | Lava Therapeutics Nv | Cooperatieve Gilde Healthcare IV U.A. | 10% | S - Sale | $1.56 | -126,992 | 5,294,178 | -2% | -$197,898 | |||||
| M | 2025-09-12 | BGMS | Bio Green Med Solution, Inc. | Kua Khai Loon | 10% | S - Sale | $5.65 | -47,251 | 338,160 | -12% | -$266,790 | |||||
2025-10-08 | BGMS | Bio Green Med Solution, Inc. | Fitters Diversified Berhad | 10% | S - Sale | $5.29 | -142,000 | 557,158 | -20% | -$751,606 | ||||||
| M | 2025-10-08 | BYSI | Beyondspring Inc. | Decheng Capital China Life Sciences Usd Fund Iii, L.P. | 10% | S - Sale | $1.78 | -13,876 | 4,313,163 | 0% | -$24,720 | |||||
| M | 2025-10-08 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $54.79 | -80,000 | 5,697,223 | -1% | -$4,383,442 | |||||
| D | 2025-10-09 | SUPN | Supernus Pharmaceuticals, Inc. | Khattar Jack A. | Pres, CEO | S - Sale+OE | $50.57 | -59,900 | 2,212,178 | -3% | -$3,029,336 | |||||
| D | 2025-10-09 | BCAX | Bicara Therapeutics Inc. | Raben David | Chief Medical Officer | S - Sale+OE | $18.45 | -22,000 | 35,497 | -38% | -$405,900 | |||||
| D | 2025-10-09 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $18.23 | -6,415 | 145,355 | -4% | -$116,931 | |||||
| DM | 2025-10-09 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $446.81 | -8,000 | 644,489 | -1% | -$3,574,444 | |||||
| D | 2025-10-08 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $350.40 | -10,671 | 223,106 | -5% | -$3,739,108 | |||||
| DM | 2025-10-08 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | Dir | S - Sale+OE | $2.42 | -121,791 | 21,232 | -85% | -$294,548 | |||||
2025-10-09 | SUPN | Supernus Pharmaceuticals, Inc. | Newhall Charles W III | Dir | S - Sale | $50.77 | -25,000 | 104,644 | -19% | -$1,269,234 | ||||||
| D | 2025-10-08 | AGIO | Agios Pharmaceuticals, Inc. | Scadden David | Dir | S - Sale+OE | $41.00 | -200 | 17,603 | -1% | -$8,200 | |||||
| D | 2025-10-08 | STOK | Stoke Therapeutics, Inc. | Kaye Edward M. Md | Dir | S - Sale+OE | $30.00 | -25,000 | 49,124 | -34% | -$750,000 | |||||
2025-10-08 | OCUL | Ocular Therapeutix, Inc | Anderman Todd | GC | S - Sale | $12.34 | -11,132 | 87,568 | -11% | -$137,369 | ||||||
2025-10-09 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $852.49 | -10,602 | 94,536,978 | 0% | -$9,038,055 | ||||||
| D | 2025-10-07 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Chief Scientific Officer | S - Sale+OE | $46.08 | -12,500 | 166,571 | -7% | -$576,001 | |||||
| D | 2025-10-07 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $89.94 | -20,000 | 5,287 | -79% | -$1,798,782 | |||||
2025-10-07 | ZBIO | Zenas Biopharma, Inc. | Moulder Leon O Jr | See Remarks | P - Purchase | $20.85 | +36,928 | 1,975,122 | +2% | +$769,949 | ||||||
2025-10-07 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $20.10 | -6,667 | 276,641 | -2% | -$133,993 | ||||||
| D | 2025-10-07 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $63.43 | -3,375 | 103,901 | -3% | -$214,091 | |||||
2025-08-19 | HOOK | Hookipa Pharma Inc. | Peters Malte | CEO | S - Sale | $0.82 | -25,172 | 54,347 | -32% | -$20,684 | ||||||
2025-10-07 | ZBIO | Zenas Biopharma, Inc. | Fairmount Funds Management LLC | Dir | P - Purchase | $19.00 | +316,219 | 2,209,025 | +17% | +$6,008,161 | ||||||
| M | 2025-10-07 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Dir | S - Sale | $70.14 | -90,000 | 972,170 | -8% | -$6,312,501 | |||||
2025-10-08 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $850.28 | -101,420 | 94,547,580 | 0% | -$86,234,874 | ||||||
| M | 2024-09-13 | ZBIO | Zenas Biopharma, Inc. | Lu Hongbo | Dir | P - Purchase | $18.63 | +321,983 | 321,983 | New | +$6,000,031 | |||||
| D | 2025-10-08 | URGN | Urogen Pharma Ltd. | Degnan Chris | CFO | S - Sale+OE | $16.85 | -2,203 | 2,280 | -49% | -$37,121 | |||||
2025-10-08 | MLTX | Moonlake Immunotherapeutics | Bodenstedt Matthias | CFO | P - Purchase | $9.09 | +10,870 | 627,536 | +2% | +$98,808 | ||||||
| DM | 2025-10-06 | AXSM | Axsome Therapeutics, Inc. | Tabuteau Herriot | CEO, 10% | S - Sale+OE | $119.38 | -45,384 | 7,351,729 | -1% | -$5,418,060 | |||||
| DM | 2025-10-06 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $16.21 | -665,159 | 1,504,959 | -31% | -$10,781,813 | |||||
2025-10-06 | SPRB | Spruce Biosciences, Inc. | Parkman Healthcare Partners LLC | 10% | P - Purchase | $17.91 | +256 | 1,050 | +32% | +$4,585 | ||||||
2025-10-06 | SPRB | Spruce Biosciences, Inc. | Parkman Healthcare Partners LLC | 10% | S - Sale | $19.14 | -257 | 1,050 | -20% | -$4,920 | ||||||
2025-10-01 | RMTI | Rockwell Medical, Inc. | Hunter Heather | SVP, COO | S - Sale | $1.19 | -2,868 | 135,391 | -2% | -$3,413 | ||||||
| DM | 2025-10-06 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO | S - Sale+OE | $14.92 | -50,292 | 214,232 | -19% | -$750,412 | |||||
2025-10-06 | IONS | Ionis Pharmaceuticals Inc | Swayze Eric | EVP Research | S - Sale | $69.02 | -6,849 | 30,637 | -18% | -$472,718 | ||||||
| D | 2025-10-06 | IONS | Ionis Pharmaceuticals Inc | O'Neil Patrick R. | EVP CLO, GC | S - Sale+OE | $69.74 | -13,441 | 53,889 | -20% | -$937,338 | |||||
2025-10-06 | IONS | Ionis Pharmaceuticals Inc | Monia Brett P | CEO | S - Sale | $69.26 | -437 | 179,572 | 0% | -$30,268 | ||||||
2025-10-06 | IONS | Ionis Pharmaceuticals Inc | Baroldi Joseph | EVP, Chief Business Officer | S - Sale | $69.37 | -1,625 | 33,372 | -5% | -$112,725 | ||||||
| D | 2025-10-06 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | CFO | S - Sale+OE | $14.52 | -11,000 | 48,317 | -19% | -$159,719 | |||||
2025-10-06 | ORIC | Oric Pharmaceuticals, Inc. | Chacko Jacob | Pres, CEO | S - Sale | $12.32 | -37,461 | 531,419 | -7% | -$461,520 | ||||||
| DM | 2025-10-06 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $18.21 | -30,385 | 145,355 | -17% | -$553,198 | |||||
| DM | 2025-10-06 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Pres, COO | S - Sale+OE | $18.06 | -50,500 | 202,641 | -20% | -$911,842 | |||||
| DM | 2025-10-07 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $451.35 | -8,000 | 644,489 | -1% | -$3,610,769 | |||||
| D | 2025-10-07 | CARM | Carisma Therapeutics Inc. | Klichinsky Michael | Chief Scientific Officer | S - Sale+OE | $0.25 | -56,982 | 0 | -100% | -$14,485 | |||||
2025-10-06 | AIMD | Ainos, Inc. | Taiwan Carbon Nano Technology Corp | 10% | S - Sale | $3.59 | -7,000 | 1,037,206 | -1% | -$25,130 | ||||||
2025-10-07 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $848.01 | -26,795 | 94,649,000 | 0% | -$22,722,401 | ||||||
| DM | 2025-10-06 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | Dir | S - Sale+OE | $2.47 | -139,412 | 81,820 | -63% | -$344,222 | |||||
2025-10-06 | CVKD | Cadrenal Therapeutics, Inc. | Szot Matthew K | CFO | S - Sale | $13.99 | -107 | 17,026 | -1% | -$1,497 | ||||||
| M | 2025-10-03 | BYSI | Beyondspring Inc. | Decheng Capital China Life Sciences Usd Fund Iii, L.P. | 10% | S - Sale | $1.78 | -20,200 | 4,327,039 | 0% | -$35,965 | |||||
| D | 2025-10-03 | PTCT | Ptc Therapeutics, Inc. | Reeve Emma | Dir | S - Sale+OE | $65.96 | -25,562 | 10,332 | -71% | -$1,686,024 | |||||
| D | 2025-10-03 | PTCT | Ptc Therapeutics, Inc. | Jacobson Allan Steven | Dir | S - Sale+OE | $65.00 | -12,000 | 17,451 | -41% | -$780,000 | |||||
| DM | 2025-10-03 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $65.75 | -24,921 | 103,901 | -19% | -$1,638,549 | |||||
| D | 2025-10-03 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | S - Sale+OE | $66.05 | -55,000 | 106,804 | -34% | -$3,632,977 | |||||
| D | 2025-10-07 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $60.56 | -2,000 | 140,610 | -1% | -$121,120 | |||||
| M | 2025-10-03 | SION | Sionna Therapeutics, Inc. | Booth Bruce | Dir | S - Sale | $29.99 | -49,546 | 3,565,781 | -1% | -$1,485,790 | |||||
| D | 2025-10-06 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $450.24 | -22,500 | 2,648 | -89% | -$10,130,439 | |||||
2025-10-03 | STOK | Stoke Therapeutics, Inc. | Kaye Edward M. Md | Dir | S - Sale | $25.09 | -42,461 | 49,124 | -46% | -$1,065,206 | ||||||
| D | 2025-10-03 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | GC, Corp Sec | S - Sale+OE | $25.07 | -10,000 | 11,831 | -46% | -$250,650 | |||||
| D | 2025-10-03 | RNA | Avidity Biosciences, Inc. | Mosbrooker Eric | Chief Commercial Officer | S - Sale+OE | $45.38 | -6,562 | 55,000 | -11% | -$297,771 | |||||
2025-10-06 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $850.22 | -161,183 | 94,675,795 | 0% | -$137,041,657 | ||||||
2025-10-03 | IMRX | Immuneering Corp | Feinberg Peter | Dir | P - Purchase | $6.67 | +7,500 | 1,141,064 | +1% | +$50,025 | ||||||
2025-10-02 | AIMD | Ainos, Inc. | Taiwan Carbon Nano Technology Corp | 10% | S - Sale | $3.59 | -2,000 | 1,044,206 | 0% | -$7,170 | ||||||
| DM | 2025-10-03 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $447.95 | -8,000 | 644,489 | -1% | -$3,583,612 | |||||
2025-10-02 | OCUL | Ocular Therapeutix, Inc | Kaiser Peter | Chief Development Officer | S - Sale | $11.03 | -9,653 | 194,440 | -5% | -$106,473 | ||||||
2025-10-02 | OCUL | Ocular Therapeutix, Inc | Heier Jeffrey S. | Chief Scientific Officer | S - Sale | $11.04 | -10,502 | 249,409 | -4% | -$115,942 | ||||||
| M | 2025-10-02 | BCYC | Bicycle Therapeutics Plc | Lee Kevin | CEO | S - Sale | $8.41 | -5,494 | 475,310 | -1% | -$46,182 | |||||
| M | 2025-10-02 | BCYC | Bicycle Therapeutics Plc | Skynner Michael | CTO | S - Sale | $8.41 | -1,802 | 118,277 | -2% | -$15,147 | |||||
| M | 2025-10-02 | BCYC | Bicycle Therapeutics Plc | Milnes Alistair | COO | S - Sale | $8.40 | -2,125 | 93,377 | -2% | -$17,860 | |||||
| M | 2025-10-02 | BCYC | Bicycle Therapeutics Plc | Hannay Michael Charles Ferguson | CHIEF PROD, SUPPLY CHAIN OFF | S - Sale | $8.40 | -723 | 53,102 | -1% | -$6,076 | |||||
2025-10-02 | BCYC | Bicycle Therapeutics Plc | Young Alethia | CFO | S - Sale | $8.51 | -482 | 44,704 | -1% | -$4,103 | ||||||
| M | 2025-10-02 | BCYC | Bicycle Therapeutics Plc | Thompson Travis Alvin | Chief Accounting Officer | S - Sale | $8.40 | -324 | 31,197 | -1% | -$2,723 | |||||
2025-10-02 | BCYC | Bicycle Therapeutics Plc | Swanton Robert Charles | Dir | S - Sale | $8.55 | -102 | 15,487 | -1% | -$872 | ||||||
2025-10-06 | CYTK | Cytokinetics Inc | Kaye Edward M. Md | Dir | S - Sale | $60.00 | -6,757 | 9,778 | -41% | -$405,420 | ||||||
2025-10-03 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $837.93 | -192,404 | 94,836,978 | 0% | -$161,220,401 | ||||||
2025-10-02 | ARQT | Arcutis Biotherapeutics, Inc. | Edwards Larry Todd | See Remarks | S - Sale | $20.04 | -4,504 | 179,324 | -2% | -$90,263 | ||||||
2025-10-03 | PMN | Promis Neurosciences Inc. | Milbury Max A. | Principal Accounting Officer | P - Purchase | $0.49 | +30,392 | 45,389 | +203% | +$14,929 | ||||||
2025-10-02 | ELTP | Elite Pharmaceuticals Inc /Nv/ | Plassche Douglas | EVP Operations | S - Sale | $0.62 | -800,000 | 3,500,000 | -19% | -$499,200 | ||||||
| DM | 2025-10-01 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | Dir | S - Sale+OE | $2.41 | -123,366 | 21,232 | -85% | -$296,789 | |||||
| M | 2025-10-01 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | Dir | S - Sale | $137.01 | -5,500 | 408,826 | -1% | -$753,560 | |||||
2025-10-02 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | CEO, COB, 10% | S - Sale | $14.13 | -500 | 402,133 | 0% | -$7,065 | ||||||
2025-10-01 | ARWR | Arrowhead Pharmaceuticals, Inc. | Hamilton James C | Chief Medical Officer | S - Sale | $35.00 | -20,000 | 212,122 | -9% | -$700,000 | ||||||
| M | 2025-10-01 | CARM | Carisma Therapeutics Inc. | Klichinsky Michael | Chief Scientific Officer | S - Sale | $0.26 | -484,347 | 0 | -100% | -$124,343 | |||||
2025-10-01 | CORT | Corcept Therapeutics Inc | Belanoff Joseph K | CEO | S - Sale | $85.08 | -40,000 | 2,781,370 | -1% | -$3,403,253 | ||||||
| D | 2025-10-01 | CORT | Corcept Therapeutics Inc | Lyon Joseph Douglas | See Remarks | S - Sale+OE | $84.75 | -5,000 | 10,277 | -33% | -$423,766 | |||||
| D | 2025-10-01 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $85.06 | -20,000 | 117,621 | -15% | -$1,701,232 | |||||
2025-10-02 | ALNY | Alnylam Pharmaceuticals, Inc. | Poulton Jeffrey V. | EVP, CFO | S - Sale | $452.05 | -3,821 | 54,109 | -7% | -$1,727,284 | ||||||
2025-10-02 | ALNY | Alnylam Pharmaceuticals, Inc. | Greenstreet Yvonne | CEO | S - Sale | $452.05 | -8,924 | 65,816 | -12% | -$4,034,085 | ||||||
2025-10-02 | ALNY | Alnylam Pharmaceuticals, Inc. | Tanguler Tolga | EVP, Chief Commercial Officer | S - Sale | $452.05 | -1,405 | 27,438 | -5% | -$635,126 | ||||||
2025-10-02 | ALNY | Alnylam Pharmaceuticals, Inc. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale | $452.05 | -2,441 | 25,768 | -9% | -$1,103,451 | ||||||
| M | 2025-10-02 | ALNY | Alnylam Pharmaceuticals, Inc. | Garg Pushkal | EVP Chief R, D | S - Sale | $451.76 | -5,959 | 20,902 | -22% | -$2,692,062 | |||||
| M | 2025-10-01 | ARQT | Arcutis Biotherapeutics, Inc. | Watanabe Todd | See Remarks | S - Sale | $19.66 | -45,000 | 1,079,574 | -4% | -$884,649 | |||||
| D | 2025-10-01 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale+OE | $18.92 | -10,000 | 99,744 | -9% | -$189,227 | |||||
2025-10-01 | KPTI | Karyopharm Therapeutics Inc. | Abate Kristin | Chief Accounting Officer | S - Sale | $6.30 | -362 | 10,046 | -3% | -$2,279 | ||||||
2025-10-01 | LGND | Ligand Pharmaceuticals Inc | Kozarich John W | Dir | S - Sale | $179.44 | -467 | 45,055 | -1% | -$83,800 | ||||||
| D | 2025-10-01 | CRNX | Crinetics Pharmaceuticals, Inc. | Pizzuti Dana | Chief Med, Dev Officer | S - Sale+OE | $41.81 | -5,000 | 66,270 | -7% | -$209,050 | |||||
| D | 2025-10-01 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | COO | S - Sale+OE | $47.76 | -12,500 | 256,898 | -5% | -$596,978 | |||||
| D | 2025-10-01 | NUVL | Nuvalent, Inc. | Balcom Alexandra | CFO | S - Sale+OE | $85.48 | -20,000 | 61,734 | -24% | -$1,709,512 | |||||
2025-10-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale | $23.64 | -5,343 | 13,126 | -29% | -$126,316 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |